Report of the French Court of Auditors on budget multiannuality

This testimony could have a significant impact in the health sector, where innovative medicines may prove to be sources of savings in the medium or long term. In order to enable funding and access to innovative therapies, it is necessary to acknowledge that their health technology assessment must be multi-factorial and part of a multi-year funding trajectory. As the Court of Auditors pointed out at the Senate Finance Committee hearing, this trajectory will have to be based on more appropriate annual indicators, in particular with regard to the Ondam (the “National Health Insurance Expenditure Target,” or “Objectif national des dépenses d’assurance maladie”), which the Court of Auditors called incomplete.

We will continue to monitor these important developments in the French Court, and advocate for appropriate health technology assessments.

Authored by Charlotte Damiano and Jean-Baptiste Chagnon